Volumetric

Volumetric, established in 2018 by Bagrat Grigoryan and Jordan Miller as a Rice University spin-out, was a prominent entity in the field of multicellular tissue engineering. The company specialized in replicating specific human body functions to facilitate fundamental biological research, laboratory testing, screening processes, and pharmaceutical development. Volumetric's long-term objective was the creation of complete human organ replacements, utilizing a patient's own cells to minimize rejection risks.

Their core innovation was a series of advanced 3D bioprinting technologies, notably featured on the cover of Science, capable of constructing human tissues with intricate vascular networks. Initially, this technology was applied to develop patient-specific tissues for drug safety and efficacy assessments. The process involved extracting cells from patient biopsies, integrating them into Volumetric's 3D-printed tissues, and simulating drug delivery through the engineered blood vessel network. Volumetric aimed to deliver reliable and predictive results, ultimately improving patient outcomes, particularly in diseases like cancer. The broader vision encompassed the production of functional tissue and organ replacements for vital organs affected by disease or damage, including the lungs, liver, pancreas, kidneys, and heart.